March 12, 2009 - Frost & Sullivan gave SENO Medical Instruments the 2009 North American Medical Imaging Emerging Company of the Year Award for pioneering the pre-clinical opto-acoustic imaging technology used to treat cancer.
Since Q3 2008 SENO Medical Instruments has announced an exclusive licensing agreement with the world leader in high frequency ultrasound VisualSonics for the rights to SENO’s opto-acoustic small animal imaging (preclinical) technology.
Frost & Sullivan Award based its decision to award Seno based on a number of factors, including product development, brand strategy, the creation of “buzz” from potential investors and customers, and strategic hiring and board appointments. Frost & Sullivan looked at outstanding management, superior market growth, exceptional customer service and the ability to combine technology and successful strategic initiatives. In the Award presentation Frost & Sullivan said SENO Medical Instruments distinguished itself in 2008 as the only company to commercially offer an opto-acoustic imaging device for preclinical imaging. This achievement, along with the establishment of research partnerships and licensing agreements with notable market participants and research centers (such as Yale, MIT, NIH, and NCI) - hallmarks the company’s impressive rapid advancement since its inception in 2005.
“Highlighting the outstanding progress SENO Medical exhibited in 2008 was the company’s assembling of a talented senior management team with the experience and vision needed to drive growth and financial success in the company’s future,” said Frost & Sullivan Industry Analyst Travis Chong. “The company is expected to leverage its collected expertise as it explores potential growth engines in 2009 including various clinical applications within cardiology and oncology.”
For more information: www.SenoMedical.com
April 24, 2024 
